Background/aims: The aim of this prospective randomized controlled trial was to investigate the need for prophylactic antibiotherapy in patients with cirrhosis and hepatocellular carcinoma who underwent transarterial embolization and to establish the parameters that determine the development of fever > 38 degrees C after this procedure.
Methods: Sixty-one consecutive patients with cirrhosis undergoing 75 procedures were randomized into Group I [(n = 37) allocated to receive prophylactic antibiotics (Cefotaxime + Metronidazole)] and Group II [(n = 38) allocated to receive no antibiotic treatment].
Results: Twelve of the 37 patients (32%) in Group I and 13 of the 38 patients (34%) in Group II developed fever > 38 degrees C after treatment. However, none of them developed bacterial infection, and all biological fluid cultures were negative. A logistic regression analysis disclosed that the obtention of an extensive tumor necrosis was the unique parameter independently associated with the development of fever.
Conclusions: Antibiotic prophylaxis is therefore not necessary in patients with cirrhosis and hepatocellular carcinoma undergoing transarterial embolization. The appearance of fever after this procedure does not indicate bacterial infection; it rather represents a clinical marker of extensive tumor necrosis and thus of a favorable response to treatment.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/0168-8278(95)80103-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Efficacy and safety of transarterial chemoembolization combined with sintilimab and bevacizumab biosimilar for unresectable hepatocellular carcinoma].
Zhonghua Nei Ke Za Zhi
February 2025
Department of Interventional Radiology, the First Affiliated Hospital of Soochow University, Suzhou215000, China.
To investigate the efficacy and safety of transarterial chemoembolization (TACE) combined with sintilimab and bevacizumab biosimilar in the treatment of unresectable hepatocellular careinoma (uHCC). The clinical data of 64 patients with unresectable HCC, who were admitted to the First Affiliated Hospital of Soochow University between January 2021 and December 2023, were retrospectively analyzed. The patients were divided into a combination group (=43, receiving TACE combined with sintilimab and bevacizumab biosimilar) and control group (=21, receiving only sintilimab and bevacizumab biosimilar).
View Article and Find Full Text PDFTrans-Arterial Embolization for Liver Metastases of Gastroenteropancreatic Neuroendocrine Tumors: Response Indicates Survival Benefit?
Cancers (Basel)
January 2025
Department of Interventional Oncology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China.
Objective: To determine the impact of trans-arterial embolization (TAE) on overall survival (OS) in patients with liver metastases from gastroenteropancreatic neuroendocrine tumors (LM-GEP-NETs) and to identify factors that may influence tumor response to TAE treatment.
Methods: This study included patients with histologically and radiologically confirmed LM-GEP-NETs who received TAE treatment at The First Affiliated Hospital, Sun Yat-sen University, between November 2016 and January 2023. Imaging responses were assessed using Response Evaluation Criteria in Solid Tumors (RECIST) 1.
TP53 Mutation Predicts Worse Survival and Earlier Local Progression in Patients with Hepatocellular Carcinoma Treated with Transarterial Embolization.
Curr Oncol
January 2025
Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
The aim of this study was to evaluate associations between TP53 status and outcomes after transarterial embolization (TAE) for the treatment of patients with hepatocellular carcinoma (HCC). This single-institution study included patients from 1/2014 to 6/2022 who underwent TAE of HCC and genomic analysis of tumoral tissue. The primary outcome was overall survival (OS) with relation to TP53 status, and the secondary outcome was the time to progression.
View Article and Find Full Text PDFRisk Factors for Postoperative Nausea and Vomiting After TACE: A Prospective Cohort Study.
Curr Oncol
December 2024
Department of Interventional Therapy, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Postoperative nausea and vomiting (PONV) was one of the common complications in patients with HCC who had undergone TACE. This study was a prospective analysis of patient data to investigate risk factors for PONV in patients after TACE. Data were collected from 212 patients undergoing TACE in the interventional department between August 2022 and August 2023.
View Article and Find Full Text PDFA Case of Radical Resection of Esophageal Basaloid Cell Carcinoma After Hemostasis by Transarterial Embolization.
Case Rep Surg
January 2025
Department of Surgery, Ise Red Cross Hospital, 1-471-2 Funae, Ise City, Mie, Japan.
Esophageal bleeding management typically involves endoscopy but becomes challenging with large or hemorrhagic tumors, especially in cases of rare basal cell carcinoma. This malignancy, with a poorer prognosis than squamous cell carcinoma, often requires definitive surgery. A 78-year-old man with severe hematemesis underwent transarterial embolization (TAE) after failed endoscopic hemostasis for a middle thoracic esophageal tumor.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!